Takeda Pharmaceutical (TAK) Capital Expenditures Growth (5y) (2023 - 2026)
Takeda Pharmaceutical (TAK) Capital Expenditures Growth (5y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.07% |
| Dec 31, 2025 | -2.85% |
| Sep 30, 2025 | -1.11% |
| Jun 30, 2025 | -9.01% |
| Mar 31, 2025 | 3.02% |
| Sep 30, 2024 | -7.13% |
| Jun 30, 2024 | -6.33% |
| Mar 31, 2024 | 12.18% |
| Dec 31, 2023 | -22.41% |
| Sep 30, 2023 | -10.52% |
| Jun 30, 2023 | -13.27% |
| Mar 31, 2023 | 11.73% |